Regeneron Drug Wins FDA Breakthrough Status for Diabetic Retinopathy
Wednesday, September 24, 2014
Source: Zacks/Analyst blog
Regeneron Pharmaceuticals' Eylea has received breakthrough therapy status from the FDA as a treatment for diabetic retinopathy among patients with diabetic macular edema. Regeneron plans to submit the drug for FDA review for this indication this year.